Eu Yan Sang

Shocking Acquisition: Japanese Giants Secure Eu Yan Sang

Japanese firms set to acquire Singapore's Eu Yan Sang for a whopping $594 million! What does this mean for traditional Chinese medicine? Find out more!

In a surprising turn of events, Japanese companies Mitsui and Rohto are sealing a massive deal to acquire the well-known traditional Chinese medicine brand, Eu Yan Sang, for a staggering $594 million. This acquisition marks a significant move in the healthcare industry, with Mitsui and Rohto venturing into the realm of Chinese herbal medicine. The founding family of Eu Yan Sang will also have a partial stake in the holding company established by Mitsui and Rohto.

On the global front, the International Organization of Securities Commissions (Iosco) is proposing stricter guidelines for the supervision of stock exchanges. This move aims to enhance regulatory oversight and ensure transparency in the financial markets. The proposal by Iosco highlights the increasing need for tighter scrutiny and regulation in the stock exchange arena.

The collaboration between Rohto Pharmaceutical and Mitsui & Co. to acquire Eu Yan Sang International signifies a strategic business move. The $800 million deal showcases the growing interest in traditional Chinese medicine on an international scale. This acquisition could potentially open doors for further investments and collaborations in the healthcare sector.

In a bid to expand their market presence, Rohto Pharmaceutical and Mitsui & Co. are set to revolutionize the traditional Chinese medicine landscape with the acquisition of Eu Yan Sang. This partnership signals a new chapter in the integration of Eastern and Western healthcare practices, paving the way for innovative developments in the industry.